Bio-Rad Laboratories (NYSE:BIO) Receives "Sell (D+)" Rating from Weiss Ratings

Key Points

• Bio-Rad Laboratories has received a "sell (D+)" rating from Weiss Ratings, amidst recent mixed assessments from other analysts.
• The company's stock price reached $305.98, with a market cap of $8.28 billion, following a reported EPS of $2.61 in its last earnings results.
• Analyst ratings for Bio-Rad include three "buy," two "hold," and one "sell," indicating a consensus rating of "hold" with a target price of $333.50.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report)'s stock had its "sell (d+)" rating reiterated by stock analysts at Weiss Ratings in a research note issued on Tuesday,Weiss Ratings reports.

Several other research analysts also recently weighed in on BIO. Zacks Research upgraded shares of Bio-Rad Laboratories from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 26th. Wall Street Zen downgraded shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Friday, August 22nd. Wells Fargo & Company increased their target price on shares of Bio-Rad Laboratories from $245.00 to $265.00 and gave the company an "equal weight" rating in a report on Friday, August 1st. Finally, Royal Bank Of Canada increased their target price on shares of Bio-Rad Laboratories from $387.00 to $409.00 and gave the company an "outperform" rating in a report on Friday, August 1st. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Bio-Rad Laboratories has a consensus rating of "Hold" and a consensus price target of $333.50.

Bio-Rad Laboratories Stock Up 0.7%

NYSE BIO traded up $2.27 on Tuesday, hitting $305.98. 41,240 shares of the company were exchanged, compared to its average volume of 308,468. The company has a market cap of $8.28 billion, a PE ratio of 26.09 and a beta of 0.97. Bio-Rad Laboratories has a 12 month low of $211.43 and a 12 month high of $387.99. The stock has a fifty day moving average of $286.62 and a 200-day moving average of $256.93. The company has a current ratio of 5.12, a quick ratio of 3.67 and a debt-to-equity ratio of 0.17.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last issued its earnings results on Thursday, July 31st. The medical research company reported $2.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.93 by $0.68. The business had revenue of $651.60 million for the quarter, compared to analyst estimates of $614.82 million. Bio-Rad Laboratories had a net margin of 12.50% and a return on equity of 4.01%. Bio-Rad Laboratories's revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the firm earned $3.11 earnings per share. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. As a group, analysts forecast that Bio-Rad Laboratories will post 10.81 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Exchange Traded Concepts LLC raised its stake in shares of Bio-Rad Laboratories by 54.9% during the third quarter. Exchange Traded Concepts LLC now owns 21,580 shares of the medical research company's stock worth $6,051,000 after acquiring an additional 7,648 shares in the last quarter. Patriot Financial Group Insurance Agency LLC increased its stake in shares of Bio-Rad Laboratories by 25.2% in the third quarter. Patriot Financial Group Insurance Agency LLC now owns 1,804 shares of the medical research company's stock worth $506,000 after buying an additional 363 shares during the period. Oak Thistle LLC increased its stake in shares of Bio-Rad Laboratories by 129.4% in the third quarter. Oak Thistle LLC now owns 3,993 shares of the medical research company's stock worth $1,120,000 after buying an additional 2,252 shares during the period. GAMMA Investing LLC boosted its holdings in Bio-Rad Laboratories by 34.5% in the third quarter. GAMMA Investing LLC now owns 987 shares of the medical research company's stock valued at $277,000 after acquiring an additional 253 shares in the last quarter. Finally, MASTERINVEST Kapitalanlage GmbH bought a new stake in Bio-Rad Laboratories in the second quarter valued at $1,077,000. 65.24% of the stock is owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.